Research programme: respiratory tract disorders small molecule therapeutics - Vectura

Drug Profile

Research programme: respiratory tract disorders small molecule therapeutics - Vectura

Alternative Names: VR 611

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Vectura
  • Class Small molecules
  • Mechanism of Action Janus kinase 1 inhibitors; Janus kinase 3 inhibitors; Janus kinase-2 inhibitors; TRPV1 receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Inflammation
  • Discontinued Cough

Most Recent Events

  • 20 May 2015 Discontinued - Preclinical for Cough in United Kingdom (Inhalation)
  • 28 May 2014 Preclinical trials in Cough in United Kingdom (Inhalation)
  • 28 May 2014 Preclinical trials in Inflammation (in respiratory tract disorders) in United Kingdom (Inhalation)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top